All Articles

Axi is the first online broker to partner with a pro golf tour. The Nguyen Report deconstructs the strategy, the risks, and why this deal is a playbook for the future.

As children return to school, many Arizona adults are starting their own educational journeys, pivoting to high-demand trades in months, not years.

Members Trust Company's appointment of Anna Weyl is more than a new hire; it's a strategic play for the complex world of ultra-high-net-worth clients.

As immigration enforcement empties classrooms, EdTrust's strategic acquisition of the National Newcomer Network signals a major new front in the battle for equity.

As the ashwagandha market booms, quality concerns rise. OmniActive's Zenroot secures USP verification, offering a trusted, low-dose solution for brands.

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

Terra Clean Energy is using 3D modeling to resurrect a historic Utah mine, betting that digital analysis of old data can fuel America's new energy future.

A pilot in Tianjin merges IoT sensors with insurance to tackle failing elevators, promising a 20% cost cut. Is this the blueprint for smart urban infrastructure?

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

The new ARIA ETF, led by an AI Ph.D., uses proprietary machine learning not to replace judgment, but to sharpen it across U.S. and Asian markets.

A powerful consortium has launched a public rescue bid for the struggling Sherritt International, igniting a battle for a key North American mineral asset.

A new survey from Ollie's reveals a stark reality: 88% of shoppers now see bargain hunting as essential, cementing the dominance of off-price retail.

With Jennifer Orlando at the helm, Juice Plus+ signals a new era, but can a new leader reshape a legacy brand in the complex direct selling landscape?

Health Canada's approval of Fasenra for HES marks a new era for patients. This is the story of how one drug intersects with patient hope and national policy.

With SEC approval, Auddia's transformative merger into AI holding company McCarthy Finney enters its final phase, setting the stage for a shareholder vote.

A landmark deal between Johnson & Johnson and ACCESS GPO is accelerating the migration of complex heart procedures to outpatient centers, a move poised to redefine costs, access, and competition in cardiac care.

Grifols completes its landmark SPARTA trial for a rare lung disease, offering new hope to patients and signaling a major strategic move in the biotech market.

CECO Environmental's record quarter, fueled by a mega-acquisition, reveals a complex story of ambition, financial nuance, and a strategic pivot to dominate.

The work management giant posted strong Q2 results but is betting its future on a radical AI pivot, cutting staff to fund a new era of automated execution.

A new "healthcare intelligence flywheel" promises to predict illness using AI and wearables. But can Pomdoctor's ambitious model navigate the realities of data privacy and market competition?